zanzalintinib (XL092) / Exelixis 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zanzalintinib (XL092) / Exelixis
2021-003243-21: Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) Estudio de XL092 + Atezolizumab frente a Regorafenib en pacientes con cáncer colorrectal metastásico (STELLAR-303)

Not yet recruiting
3
600
Europe
XL092, Atezolizumab, Regorafenib, XL092, RO5541267, Film-coated tablet, Concentrate for solution for infusion, TECENTRIQ, Stivarga
Exelixis, Inc., Exelixis, Inc.
Metastatic colorectal cancer (CRC) Cáncer colorrectal metastásico, Colorectal cancer Cáncer colorrectal, Diseases [C] - Cancer [C04]
 
 
STELLAR-304, NCT05678673: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Recruiting
3
291
Europe, US, RoW
XL092, Nivolumab, Opdivo®, Sunitinib Malate, Sutent®
Exelixis
Non-Clear Cell Renal Cell Carcinoma
07/25
06/28
STELLAR-303, NCT05425940 / 2021-003243-21: Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Active, not recruiting
3
874
Europe, US, RoW
XL092, Atezolizumab, Tecentriq®, Regorafenib, Stivarga®
Exelixis, Exelixis, Inc.
Colorectal Cancer
08/25
02/26
STELLAR-305, NCT06082167: Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
2/3
600
Europe, US, RoW
Zanzalintinib, XL092, Zanzalintinib-matched Placebo, XL092-matched Placebo, Pembrolizumab, KEYTRUDA®
Exelixis, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
08/28
03/29
NCT06571734: XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Recruiting
2
29
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Zanzalintinib, Multi-kinase Inhibitor XL092, XL 092, XL-092, XL092
Northwestern University, National Cancer Institute (NCI)
Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma
07/25
07/26
PRO-XL, NCT06568562: XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
32
US
XL092, Zanzalintinib
University of Utah, Exelixis
Metastatic Castration-resistant Prostate Cancer
12/26
12/28
NCT06698250: Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Recruiting
2
40
US
Zanzalintinib, XL-092, Durvalumab, Imfinzi, Tremelimumab, Imjudo
Anwaar Saeed, Exelixis
Hepatocellular Carcinoma
12/26
04/27
EXPLORE-RCC, NCT06794229: Neoadjuvant Zanzalintinib Plus Nivolumab in Patients with Locally Advanced And/or Inoperable Clear Cell Renal Cell Carcinoma with or Without Non-measurable Metastasis

Not yet recruiting
2
69
NA
Zanzalintinib, XL092, Nivolumab, Opdivo
Qian Qin, Exelixis, University of Texas
Locally Advanced Renal Cell Carcinoma
06/28
06/29
STELLAR-009, NCT06191796: Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors

Active, not recruiting
1/2
25
US
zanzalintinib, XL092, AB521, Nivolumab, OPDIVO®
Exelixis, Arcus Biosciences, Inc.
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
01/26
01/27
Morpheus Lung, NCT03337698 / 2017-001267-21: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Checkmark Combo atezolizumab
Nov 2017 - Nov 2017: Combo atezolizumab
Active, not recruiting
1/2
314
Europe, US, RoW
Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Zanzalintinib, Camonsertib
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
09/25
11/26
STELLAR-001, NCT03845166: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Active, not recruiting
1
325
Europe, US, RoW
XL092, Atezolizumab, Tecentriq®, Avelumab, Bavencio®
Exelixis
Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
08/26
05/27
NCT06795009: Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Not yet recruiting
1
36
US
Zanzalintinib, XL092, Paclitaxel, Taxol
Washington University School of Medicine, National Cancer Institute (NCI), Exelixis
Uterine Cancer, Endometrial Cancer
06/29
11/34
STELLAR-002, NCT05176483: Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Recruiting
1
1274
Europe, US, RoW
Zanzalintinib, XL092, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab
Exelixis
Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma, Solid Tumor, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
02/26
05/26

Download Options